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Lysine is proposed as an alternative biosynthetic precursor of the pyrrole-imidazole alkaloids frequently
found in marine sponges. As a putative key intermediate, the natural product NR-(4-bromopyrrolyl-2-
carbonyl)-L-homoarginine (1) from the sponge Agelas wiedenmayeri was synthesized in the solid phase
starting from Fmoc/Pmc-protected L-homoarginine and in solution starting from readily available L-lysine
methyl ester.
Pyrrole-imidazole alkaloids continue to be isolated from
marine sponges and represent one of the most prominent
groups of natural products exclusive to the marine environ-
ment.1 The underlying C11N5 building block consists of a
pyrrolyl-2-carbonyl unit being connected via an amide
linkage to a 2-amino-5-(3-amino)propylimidazole partial
structure. Recently, NR-(4-bromopyrrolyl-2-carbonyl)-
homoarginine (1) was isolated from the marine sponge
Agelas wiedenmayeri,2a together with known pyrrole-
imidazole alkaloids such as oroidin (2).3 In this paper, we
describe solid-2b and solution-phase syntheses of 1 and the
determination of its absolute configuration. After the
discovery of the aplysinamisines I and II from Aplysina
cauliformis,4 1 and 2 constitute a new pair of natural
products pointing at a biogenetic relationship between
lysine and 2-amino-5-(3-amino)propenylimidazoles in ma-
rine sponges. Oroidin (2) contributes to the survival of the
genus Agelas by protecting the sponge against predation
by the reef fish Thalassoma bifasciatum.5
The solid-phase synthesis of 1 (Scheme 1) was achieved
starting from (Fmoc/Pmc)-protected L-homoarginine (3),
which was coupled to 2-chlorotrityl chloride polystyrene
resin (4), forming compound 5. After removal of the Fmoc-
protecting group with 40% piperidine in DMF, 4-bromopyr-
role-2-carboxylic acid (6) was attached using DIC/HOBt as
coupling reagents. Finally, treatment of the product 7 with
98% TFA led to the removal of the Pmc group and to the
cleavage of NR-(4-bromopyrrolyl-2-carbonyl)-L-homoargi-
nine (L-1) from the resin. The overall yield was 72%.
Alternatively, reaction of L-lysine methyl ester (8, Scheme
2) with the bis-Boc-protected pyrazole-1H-carboxamidine
116 regioselectively gave the protected homoarginine 12,
which was further converted to the methyl ester 14 via
reaction with the pyrrolyltrichloromethyl ketone 13.7 Treat-
ment of 14 with HCl(g)/Et2O led to the selective removal
of the Boc groups. Hydrolysis with 8 N HCl provided the
natural product L-1 as the hydrochloride in 60% overall
yield. Reaction of 8 with 9 in acetonitrile/N,N-diisopropyl-
ethylamine8 led to the selective acylation of the -amino
group to 10.
The UV maxima of 1 in aqueous phosphate buffer, pH
7, were observed at 272 ( 3.99) and 202 ( 3.89) nm, while
the CD spectrum (Figure 1) exhibited only one significant
minimum. The still undetermined absolute configuration
of the natural product 1 was established as L on the basis
of negative Cotton effects at 216 nm (∆ -1.6) for the
synthetic L-1 and at 214 nm (∆ -1.6) for the natural
product 1. At 270 nm, the CD is not intense enough to be
useful for the assignment of the absolute stereochemistry
of the NR-pyrrolylcarbonyl amino acid 1; L-1 shows a
negative optical rotation.
Several alternatives have been discussed with regard to
the biosynthesis of the pyrrole-imidazole alkaloids. While
the pyrrole part is generally expected to derive from
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Scheme 1. Solid-Phase Synthesis of L-1a
a (a) 4, CH2Cl2, i-Pr2NEt, room temperature, 3 h; (b) piperidine/DMF,
room temperature, 3 × 20 min; (c) 6, DIC, HOBt, DMF, room temperature,
5 h; (d) TFA, room temperature, 30 min, 72% from 3.
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proline/ornithine, different proposals have been put for-
ward for the 2-amino-5-(3-amino)propylimidazole part.
Recently, the first experimental study on the biosynthesis
of the pyrrole-imidazole alkaloid stevensine was per-
formed by Pomponi, Kerr, and co-workers.9 The incorpora-
tion of histidine might proceed via an analogue of clath-
ramide A10 (17, Figure 2) isolated from the oroidin source
Agelas clathrodes. The C-methylation of the imidazoline
ring of 17 could provide the carbon atom required for chain
elongation, for example, via a cyclopropanoid intermediate.
Kitagawa et al.11 and Braekman et al.12 proposed ornithine
as a biogenetic precursor, with the carboxyl carbon atom
being incorporated into the imidazole ring and the R- and
δ-amino groups incorporated into the imidazole ring and
the side chain, respectively.
The discovery of the aplysinamisines and of the ho-
moarginine derivative 1, together with the co-occurrence
of lysine and bromopyrroles in marine sponges,13 points to
the existence of an alternative biosynthesis (Figure 2). In
analogy to the role of 4-hydroxyarginine as a biosynthetic
precursor of the 2-aminoimidazoline anatoxin-a(s),14 δ-hy-
droxyhomoarginine (15) is postulated as an intermediate
in the biosynthesis of 5-(3-aminopropyl)-2-aminoimidazoles.
Intramolecular cyclization of 15 would lead to a 2-ami-
noimidazoline, which would be further oxidized and un-
dergo decarboxylation. The aminohomohistamine 16 with
its saturated side chain is a partial structure of the marine
natural product aerophobin-2 from Aplysina aerophoba.15
Horne et al. have shown that by oxidation of 16 (R )
dibromopyrrolyl-2-carbonyl) the vinyl double bond of oro-
idin (2) can be introduced.16 The formation of the putative
intermediate 15 could occur via the guanidinylation of
lysine to an analogue of the natural product 1, followed by
δ-hydroxylation.
Experimental Section
General Experimental Procedures. The melting points
are uncorrected. NMR chemical shifts refer to those of residual
solvent signals based on δTMS ) 0. FABMS were obtained with
nitrobenzyl alcohol as matrix. Solvents were purified and dried
according to standard procedures.17 Column chromatography
was carried out on Si gel 60 (60-200 mesh, Merck) and on
Sephadex LH-20 (Pharmacia). HPLC separation columns
(analytical: 4.6 × 250 mm, 5 µm; preparative: 20 × 250 mm,
7 µm) were pre-filled with Kromasil RP18 (Knauer GmbH). CD
spectra were obtained using the JASCO spectropolarimeter
J-710. Thin-layer chromatography (TLC) was performed on Si
gel (precoated Si gel plate F254 Merck).
4-Bromopyrrole-2-carboxylic Acid (6). Ethyl pyrrole-2-
carboxylate18 was brominated and then hydrolyzed according
to Anderson and Lee.19 After purification by preparative
reversed-phase HPLC (gradient: 5 min A, 0-40% B in 45 min;
A: 10% MeCN/H2O + 0.1% TFA, B: 100% MeCN+ 0.1% TFA;
flow rate 10 mL/min) 6 was frozen in liquid nitrogen and
freeze-dried to afford 1.19 g (33%) of a white-gray powder; mp
142 °C (dec); tR 12.73 min (gradient: 20-60% MeCN/H2O +
0.1% TFA in 40 min; flow rate 1 mL/min); UV (MeOH) λmax
(log ) 264 (4.05) nm; IR (KBr) νmax 3357, 3133, 2924, 1685,
1550, 1432, 1366, 1326, 1206, 1121 cm-1; 1H NMR (DMSO-d6,
250 MHz) δ 12.11 (1H, NH), 7.10 (1H, CH), 6.75 (1H, CH); 13C
NMR (DMSO-d6, 63 MHz) δ 161.0 (1C, COOH), 123.8 (1C,
NHCCO), 123.3 (1C, NHCHCBr), 115.8 (1C, CBrCHC), 95.7
(1C, CBr); ESIMS (neg) m/z 188 (100) 190 (99); HRFABMS
m/z 188.9420 [M + H]+ (calcd for C5H4N1O279Br, 188.9426).
(2S)-2-{[1-(4-Bromo-1H-pyrrol-2-yl)methanoyl]amino}-
6-guanidinohexanoic Acid (L-1). To a suspension of 2-chlo-
rotrityl chloride resin (4, 1.00 g, copoly(styrene-2% DVB), 200-
400 mesh, Novabiochem) in CH2Cl2 (4 mL) Fmoc-Homoarg-
(Pmc)-OH (3, 500 mg, 0.74 mmol, BACHEM), dissolved in
CH2Cl2 (1 mL), was added. During the addition of N,N-
diisopropylethylamine (380 µL, 2.22 mmol), the yellow reaction
mixture turned immediately violet. After shaking for 3 h at
room temperature a 3-fold excess of N,N-diisopropylethylamine
and MeOH (3 mL) was added, and the mixture was shaken
for 15 min. After filtering off the liquid phase, the resin was
washed (2 × 5 min each time) with CH2Cl2 (10 mL), i-PrOH
(10 mL), and Et2O (10 mL). The resin was then resuspended
for 3 × 20 min in DMF (5 mL) and shaken at room temper-
ature. For removal of the Fmoc-protecting group, the resin was
Scheme 2. Solution-Phase Synthesis of L-1a
a (a) 9, i-Pr2NEt, CH3CN, room temperature, 3 h, 75%; (b) 11, i-Pr2NEt,
CH3CN, room temperature, 24 h, 80%; (c) 13, i-Pr2NEt, CH3CN, 24 h, 89%;
(d) 8 N HCl, room temperature, 4 h, 85%.
Figure 1. CD spectrum of synthesized natural product L-1 (2,2,2-
trifluoroethanol, c ) 1.5 mM).
Figure 2. Proposal of the lysine-derived δ-hydroxyhomoarginine (15)
as an alternative biogenetic precursor of the 2-amino-5-(3-amino)-
propylimidazoles.
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shaken 3 × 20 min each time with a solution of piperidine in
DMF (40%, 5 mL). Afterward the resin was washed 4 × 5 min
with DMF (10 mL). Then a solution of 4-bromopyrrole-2-
carboxylic acid (6, 422 mg, 2.22 mmol) and 1-hydroxybenzo-
triazol (450 mg, 3.33 mmol) in DMF (5 mL) was added, and
the mixture was shaken for 2 min at room temperature. After
the addition of N,N-diisopropylcarbodiimide (404 µL, 2.59
mmol), the mixture was allowed to shake for 5 h at room
temperature. The reaction mixture was then removed using
air pressure, and the remaining resin was washed twice for 5
min with CH2Cl2 (10 mL), i-PrOH (10 mL), and Et2O (10 mL).
Finally, the resin was treated with 98% TFA (5 mL) and
shaken for 30 min at room temperature. The liquid phase was
collected, and the resin was washed (2 × 5 min each) with
H2O (2 × 10 mL) and MeCN (2 × 10 mL). Both the acid
reaction solution and washings were combined, frozen with
liquid nitrogen, and freeze-dried. The obtained crude white
powder was purified by preparative reversed-phase HPLC
(gradient: 5 min A, 0-40% B in 45 min; A: 10% MeCN/H2O
+ 0.1% TFA, B: 100% MeCN + 0.1% TFA; flow rate 10 mL/
min). The purified HPLC fraction was frozen and freeze-dried
yielding 100 mg (72%) of L-1 as white powder; tR 7.85 min
(gradient: 20-60% MeCN/H2O + 0.1% TFA in 40 min; flow
rate 1 mL/min); UV (H2O) λmax (log ) 271 (4.06) nm; CD (H2O)
λ (∆) 216 (-1.6) nm; IR (KBr) νmax 3379, 3199, 2943, 2871,
1670, 1520, 1386, 1203, 1136 cm-1; 1H NMR (DMSO-d6, 250
MHz,) δ 11.87 (1H, NH), 8.14 (1H, NH), 7.41 (1H, NH), 6.96
(1H, CH), 6.91 (1H, CH), 4.25 (dt, J ) 4.9 Hz, 1H, CH), 3.05
(d, J ) 5.3 Hz, 2H, CH2NH), 1.73 (m, 2H, CHCH2), 1.47 (m,
2H, CH2CH2NH), 1.37 (m, 2H, CHCH2CH2); 13C NMR (DMSO-
d6, 63 MHz) δ 174.9 (1C, COOH), 159.2 (1C, CONH), 157.0
(1C, NCNHNH2), 126.9 (1C, NHCCO), 121.1 (1C, NHCHCBr),
111.9 (1C, CBrCHC), 95.0 (1C, CBr), 52.8 (1C, CH), 40.6 (1C,
CH2NH), 31.2 (1C, CHCH2), 28.3 (1C, CH2CH2NH), 22.9 (1C,
CHCH2CH2); ESIMS (neg) m/z 358 (82), 360 (82); HRFABMS
m/z 360.0663 [M + H]+ (calcd for C12H19N5O379Br, 360.0672).
(2S)-2-Amino-6-[1-(4,5-dibromo-1H-pyrrol-2-yl-metha-
noyl)amino]hexanoic Acid Methyl Ester (10). To a solu-
tion of L-lysine methyl ester hydrochloride (8, 200 mg, 0.86
mmol) in acetonitrile (3 mL) was added 2,2,2-trichloro-1-(4,5-
dibromo-1H-pyrrol-2-yl)ethanone (9, 318 mg, 0.86 mmol) and
N,N-diisopropylethylamine (0.3 mL, 1.81 mmol). After 3 h at
room temperature, the solvent was evaporated, and the crude
residue was purified by column chromatography (Si gel, CHCl3/
MeOH/NH3aq 40:10:1) to yield 10 as colorless oil (265 mg, 75%);
Rf 0.5 (CHCl3/MeOH/NH3aq 40:10:1); UV (MeOH) λmax (log )
204 (3.92), 218 (3.84, sh), 236 (3.79, sh), 274 (4.15) nm; IR
(KBr) νmax 3369, 3300, 3116, 2939, 2857, 1734, 1628, 1560,
1525 cm-1; 1H NMR (DMSO-d6, 360 MHz) δ 8.05 (1H, t, J )
5.3 Hz, NHCOC), 6.88 (1H, s, CBrCHC), 3.60 (3H, s, CO2CH3),
3.30 (1H, m, CHCH2), 3.18 (2H, m, CH2NH), 1.60-1.25 (6H,
m, CHCH2CH2CH2); 13C NMR (DMSO-d6, 90.6 MHz) δ 176.1
(1C, CO2CH3), 158.9 (1C, NHCO), 128.5 (1C, NHCCO), 112.3
(1C, CBrCHC), 104.4 (1C, CBr), 97.6 (1C, CBr), 53.8 (1C, CH),
51.4 (1C, OCH3), 38.4 (1C, CH2NH), 34.1 (1C, CHCH2), 29.0
(1C, CH2CH2NH), 22.6 (1C, CHCH2CH2); FABMS m/z 410/412/
414 (10/19/10) [M + H]+, 251/252/253 (4/10/4), 154 (20), 136
(22), 84 (100); HRFABMS m/z 409.9707 (calcd for C12H18N3O3-
79Br2, 409.9715); anal. C 35.76%, H 4.47%, N 10.28%, calcd
for C12H17N3O3Br2, C 35.46%, H 4.17%, N 10.22%.
(2S)-2-Amino-6-[N,N′-bis(tert-butoxycarbonyl)guanidi-
no]hexanoic Acid Methyl Ester (12). To a solution of
L-lysine methyl ester hydrochloride (8, 1.16 g, 5.00 mmol) and
N,N-diisopropylethylamine (1.85 mL, 10.5 mmol) in MeCN (25
mL) was added 1H-pyrazole-1-[N,N′-bis(tert-butoxycarbonyl)]-
carboxamidine (11, 1.55 g, 5.00 mmol). After 24 h at room
temperature, the reaction mixture was filtered, and the solvent
was evaporated. The crude residue was purified by column
chromatography (Si gel, CHCl3/MeOH 20:1) to yield 12 as
colorless oil (1.61 g, 80%); Rf ) 0.4 (CHCl3/MeOH 10:1); [R]20D
+11° (c 0.01, MeOH); UV (MeOH) λmax (log ) 216 (3.98), 236
(4.09) nm; IR (KBr) νmax 3333, 3140, 2979, 2865, 1728, 1644
cm-1; 1H NMR (CDCl3, 250 MHz) δ 11.49 (1H, br s, NH), 8.31
(1H, br s, NH), 3.72 (3H, s, OCH3), 3.43 (3H, m, CH, CH2NH),
2.17 (2H, br s, NH2), 1.50 (9H, s, C(CH3)3), 1.49 (9H, s,
C(CH3)3), 1.80-1.41 (6H, m, CH2CH2CH2); 13C NMR (CDCl3,
63 MHz) δ 176.4 (1C, CO2CH3), 163.6 (1C, CO), 156.1 (1C,
NHCNNH), 153.3 (1C, CO), 83.0 (1C, C(CH3)3), 79.2 (1C,
C(CH3)3), 54.2 (1C, CH), 51.9 (1C, OCH3), 40.6 (1C, CH2NH),
34.5 (1C, CHCH2), 28.8 (1C, CH2CH2NH), 28.3 (3C, C(CH3)3),
28.0 (3C, C(CH3)3), 23.0 (1C, CHCH2CH2); FABMS m/z 403
(4) [M + H]+, 203 (75), 126 (12), 84 (40), 60 (12), 57 (100);
HRFABMS m/z 403.2570 (calcd for C18H35N4O6, 403.2557);
anal. C 53.42%, H 8.43%, N 13.62%, calcd for C18H34N4O6, C
53.72%, H 8.51%, N 13.92%.
(2S)-2-{[1-(4-bromo-1H-pyrrol-2-yl)methanoyl]amino}-
6-[N,N′-bis(tert-butoxycarbonyl)guanidino]hexanoic
Methyl Ester (14). To a solution of 12 (400 mg, 1.00 mmol)
in MeCN (3 mL) was added 2,2,2-trichloro-1-(4-bromo-1H-
pyrrol-2-yl)ethanone (13, 270 mg, 1.00 mmol) and N,N-
diisopropylethylamine (0.20 mL, 1.10 mmol). After 24 h at
room temperature, the solvent was evaporated, and the crude
residue was purified by column chromatography (Si gel, CHCl3/
MeOH 50:1) to yield 14 as colorless foam (511 mg, 89%); Rf
0.6 (CHCl3/MeOH 10:1); [R]20D -10° (c 0.02, MeOH); UV
(MeOH) λmax (log ) 208 (4.26), 234 (4.37), 270 (4.01) nm; IR
(KBr) νmax 3331, 2979, 1721, 1647 cm-1; 1H NMR (CDCl3, 250
MHz) δ 11.48 (1H, br s, NH), 10.64 (1H, br s, NH), 8.33 (1H,
br s, NH), 6.89 (1H, m, CBrCHC), 6.84 (1H, m, NH), 6.74 (1H,
m, NHCHCBr), 4.72 (1H, m, NHCHCO2CH3), 3.76 (3H, s,
OCH3), 3.38 (2H, m, CH2NH), 1.56 (18H, s, C(CH3)3), 2.00-
1.30 (6H, m, CH2CH2CH2); 13C NMR (CDCl3, 63 MHz) δ 172.8
(1C, CO2CH3), 163.4 (1C, CO), 160.1 (1C, CONHCH), 156.1
(1C, NHCNNH), 153.2 (1C, CO), 125.4, (1C, CHCCO), 122.0
(1C, CBrCHNH), 112.2 (1C, CBrCHC), 96.8 (1C, CBr), 83.0
(1C, C(CH3)3), 79.2 (1C, C(CH3)3), 52.3 (1C, CH), 52.0 (1C,
OCH3), 40.3 (1C, CH2NH), 31.8 (1C, CHCH2), 28.4 (1C, CH2-
CH2NH), 28.2 (3C, C(CH3)3), 27.9 (3C, C(CH3)3), 22.6 (1C,
CHCH2CH2); FABMS m/z 574/576 (0.6/0.5) [M +H]+, 374/376
(6/7). 84 (16), 57 (100); HRFABMS m/z 574.1914 (calcd for
C23H37N5O779Br, 574.1876).
(2S)-2-{[1-(4-Bromo-1H-pyrrol-2-yl)methanoyl]amino}-
6-guanidinohexanoic Acid Methyl Ester. A solution of 14
(100 mg, 0.17 mmol) in MeOH (20 mL) was saturated with
HCl gas at 0 °C and stirred for 30 min at room temperature.
The solvent was evaporated, and the residue was purified by
column chromatography (Si gel, n-BuOH/HOAc/H2O 3:1:1) to
yield L-1 methyl ester as pale yellow solid (64 mg, 90%); Rf )
0.5 (Si gel, n-BuOH/HOAc/H2O 3:1:1); [R]20D -9° (c 0.01,
MeOH); UV (MeOH) λmax (log ) 204 (4.05), 234 (3.98, sh), 276
(4.34) nm; IR (KBr) νmax 3416, 3266, 3177, 2950, 2863, 1734,
1653 cm-1; 1H NMR (MeOH-d4, 250 MHz) δ 6.94 (1H, s, CH),
6.93 (1H, s, CH), 4.54 (1H, m, CH), 3.73 (3H, s, OCH3), 3.18
(2H, t, J ) 6.5 Hz, CH2NH), 1.92 (2H, m, CHCH2), 1.63 (2H,
m, CH2CH2NH), 1.50 (2H, m, CHCH2CH2); 13C NMR (MeOH-
d4, 63 MHz) δ 174.2 (1C, CO2H), 162.5 (1C, CONHCH), 158.6
(1C, NHCNNH), 127.0 (1C, CHCCO), 123.2 (1C, CBrCHNH),
114.2 (1C, CBrCHC), 97.6 (1C, CBr), 53.5 (1C, CH), 52.8 (1C,
OCH3), 42.3 (1C, CH2NH), 32.0 (1C, CHCH2), 29.3 (1C, CH2-
CH2NH), 24.2 (1C, CHCH2CH2); FABMS m/z 374/376 (99/100)
[M +H]+; HRFABMS m/z 376.0793 (calcd for C13H21N5O379Br,
376.0807).
(2S)-2-{[1-(4-Bromo-1H-pyrrol-2-yl)methanoyl]amino}-
6-guanidinohexanoic Acid (L-1). Compound 14 (200 mg,
0.35 mmol) was suspended in aqueous HCl (8 N, 8 mL) and
stirred 4 h at room temperature. The solution was concen-
trated in vacuo to dryness and purified by column chroma-
tography (Si gel, n-BuOH/HOAc/H2O 3:1:1) to afford L-1 as pale
orange solid (118 mg, 85%); Rf 0.6 (n-BuOH/HOAc/H2O 3:1:
1); [R]20D -11° (c 0.03, MeOH); UV (aqueous phosphate buffer,
pH 7) λmax (log ) 202 (3.89), 272 (3.99) nm; CD (CF3CH2OH)
λ (∆) 217 (-1.8) nm; IR (KBr) νmax 3330, 3277, 3199, 2940,
2863, 1718, 1633 cm-1; 1H NMR (MeOH-d4, 250 MHz) δ 6.94
(1H, s, CH), 6.93 (1H, s, CH), 4.54 (1H, m, CH), 3.18 (2H, t, J
) 6.5 Hz, CH2NH), 2.05-1.93 (1H, m, CHCH2), 1.89-1.75 (1H,
m, CHCH2), 1.71-1.56 (2H, m, CH2CH2NH), 1.55-1.41 (2H,
m, CHCH2CH2); 13C NMR (MeOH-d4, 63 MHz) δ 175.5 (1C,
COOH), 162.5 (1C, NCNHNH2), 158.6 (1C, CONH), 127.1 (1C,
NHCCO), 123.1 (1C, NHCHCBr), 114.2 (1C, CBrCHC), 97.6
(1C, CBr), 53.4 (1C, CH), 42.3 (1C, CH2NH), 32.2 (1C, CHCH2),
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29.3 (1C, CH2CH2NH), 24.3 (1C, CHCH2CH2); FABMS m/z 382/
384 (84/86) [M + Na]+, 360/362 (80/80) [M]+; HRFABMS m/z
382.0486 (calcd for C12H18N5O379BrNa, 382.0491).
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